Telomir Pharmaceuticals Inc (TELO) Stock Price, Quote & News

Company Profile

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharma...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 396 6723

Website: telomirpharma.com

Address:

100 SE 2nd Street, Suite 2000 #1009, Miami, United States

FavoredTrades Oct. 3 at 2:51 PM

$TELO With the partnership that could most likely come. There will be no secrets, insiders will be buying in an obvious way

0 · Reply

Br_Hearing Oct. 3 at 1:44 PM

$TELO Can expect basically sideways movement until the next report either clinical or earnings. This isnt a meme stock until out of nowhere it gets bought out by a larger pharma

0 · Reply

BestNwest Oct. 2 at 4:36 PM

$TELO price target 4$-15$

0 · Reply

andrew_228 Oct. 1 at 3:46 PM

$TELO Abysmal volume lately, but price is stay relatively flat. Good consolidation. Nice base for the launch.

0 · Reply

Br_Hearing Sep. 30 at 2:27 PM

Been a $TELO holder for months now. BioTech is about a big a risk there is in equities but every time they report results of trials its a positive one. this is one of those holds where one day you wake up to find out they were bought by pfizer for 10 dollars a share

0 · Reply

Wildblitz Sep. 29 at 5:10 PM

$CLIK $HCTI $TELO Nice start to another craptastic week

0 · Reply

Buckeyeguy337 Sep. 29 at 1:44 PM

$TELO this is a great entry price before the 2026 bull run. Will easily 3x in price soon

0 · Reply

BestNwest Sep. 29 at 1:45 AM

$TELO 15$++the future is here!

0 · Reply

ChartChartist Sep. 28 at 8:37 PM

$HOTH 1.45 support $AYTU 1.50 bid $TELO 50ma $PHH hearing there it goes $PAVS Everyone seems to be slapping pavs, running after hours friday. Rocket setup for a trade. Slap early.

1 · Reply

Washingtonstate Sep. 28 at 10:39 AM

$TELO

0 · Reply

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

Sep 9, 2025, 8:00 AM EDT - 25 days ago

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy

Aug 28, 2025, 8:00 AM EDT - 5 weeks ago

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

Jul 24, 2025, 8:00 AM EDT - 2 months ago

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

Jul 18, 2025, 8:00 AM EDT - 2 months ago

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

Jun 18, 2025, 9:15 AM EDT - 3 months ago

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

Jun 11, 2025, 9:30 AM EDT - 4 months ago

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Jun 5, 2025, 8:30 AM EDT - 4 months ago

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Jun 2, 2025, 8:30 AM EDT - 4 months ago

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

May 29, 2025, 8:30 AM EDT - 4 months ago

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

May 21, 2025, 9:00 AM EDT - 4 months ago

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

May 15, 2025, 8:00 AM EDT - 5 months ago

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

May 7, 2025, 8:00 AM EDT - 5 months ago

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

Mar 19, 2025, 8:00 AM EDT - 7 months ago

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Feb 26, 2025, 8:00 AM EST - 7 months ago

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

Feb 21, 2025, 8:00 AM EST - 8 months ago

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

Feb 18, 2025, 8:00 AM EST - 8 months ago

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

Jan 28, 2025, 8:00 AM EST - 8 months ago

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Jan 7, 2025, 8:00 AM EST - 9 months ago

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

Dec 23, 2024, 7:30 AM EST - 10 months ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Dec 12, 2024, 8:30 AM EST - 10 months ago

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Dec 3, 2024, 1:40 PM EST - 10 months ago

Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?

Dec 3, 2024, 7:30 AM EST - 10 months ago

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Nov 21, 2024, 7:00 AM EST - 11 months ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Sep 26, 2024, 4:00 PM EDT - 1 year ago

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Aug 20, 2024, 7:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Jun 17, 2024, 4:10 PM EDT - 1 year ago

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

May 30, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Apr 16, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Mar 29, 2024, 4:44 PM EDT - 1 year ago

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Mar 26, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Mar 22, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Mar 14, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science

Mar 7, 2024, 8:30 AM EST - 1 year ago

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Mar 5, 2024, 8:30 AM EST - 1 year ago

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

Feb 13, 2024, 4:05 PM EST - 1 year ago

Telomir Pharmaceuticals Announces Closing of Initial Public Offering

Dec 16, 2023, 12:25 PM EST - 1 year ago

IPO Update: Telomir Pharmaceuticals Proposes IPO Terms

FavoredTrades Oct. 3 at 2:51 PM

$TELO With the partnership that could most likely come. There will be no secrets, insiders will be buying in an obvious way

0 · Reply

Br_Hearing Oct. 3 at 1:44 PM

$TELO Can expect basically sideways movement until the next report either clinical or earnings. This isnt a meme stock until out of nowhere it gets bought out by a larger pharma

0 · Reply

BestNwest Oct. 2 at 4:36 PM

$TELO price target 4$-15$

0 · Reply

andrew_228 Oct. 1 at 3:46 PM

$TELO Abysmal volume lately, but price is stay relatively flat. Good consolidation. Nice base for the launch.

0 · Reply

Br_Hearing Sep. 30 at 2:27 PM

0 · Reply

Wildblitz Sep. 29 at 5:10 PM

$CLIK $HCTI $TELO Nice start to another craptastic week

0 · Reply

Buckeyeguy337 Sep. 29 at 1:44 PM

$TELO this is a great entry price before the 2026 bull run. Will easily 3x in price soon

0 · Reply

BestNwest Sep. 29 at 1:45 AM

$TELO 15$++the future is here!

0 · Reply

ChartChartist Sep. 28 at 8:37 PM

$HOTH 1.45 support $AYTU 1.50 bid $TELO 50ma $PHH hearing there it goes $PAVS Everyone seems to be slapping pavs, running after hours friday. Rocket setup for a trade. Slap early.

1 · Reply

Washingtonstate Sep. 28 at 10:39 AM

$TELO

0 · Reply

WavRyder Sep. 27 at 4:58 PM

$TELO Given how Telomir1 works, the company is sitting a gold mine. IND this year and successful clinical II trials will rock the industry, as it will benefit everyone on this planet.

0 · Reply

FavoredTrades Sep. 26 at 6:47 PM

$TELO Tested 1.60 and failed. Looking for bottom. Needs solid updates

1 · Reply

Wildblitz Sep. 26 at 6:19 PM

$TELO $HCTI $CLIK - another craptastic week for these turds

0 · Reply